Woliver Cory, Kastenholz Victoria, Southern Carl, Odunayo Adesola, Schaer Michael, Allen-Durrance Ashley
J Am Vet Med Assoc. 2025 Jul 30:1-7. doi: 10.2460/javma.25.04.0275.
To describe the use of varespladib, a synthetic, small molecule secretory phospholipase A2 (sPLA2) inhibitor, in the treatment of severe eastern coral snake envenomation with signs of neurotoxicity.
3 dogs presenting to a tertiary referral academic teaching hospital.
3 dogs with tetraparesis, hypoventilation, and other clinical signs of eastern coral snake (Micrurus fulvius) envenomation presented to a tertiary referral academic teaching hospital between September 1, 2024, and March 30, 2025, and were treated with varespladib, coral snake antivenom, and supportive care.
All dogs made a complete and expedited recovery. None of the dogs required mechanical ventilation. The total hospitalization time for each dog was approximately 50 to 70 hours, significantly shorter than the previously published hospitalization duration (187 to 196 hours) without intervention with varespladib. No adverse effects were attributed to varespladib or antivenom administration.
Varespladib may have a role in shortening the duration of the clinical signs of dogs envenomated by coral snakes and may reduce the need for mechanical ventilation in affected dogs.
